Early Trials Test Vaccines for Lynch-Linked and Pancreatic Precancers
Early results showed strong immune responses and shrinkage or stabilization in some lesions, but researchers said the trials do not prove cancer prevention.
- Researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins conducted a trial of the mKRAS-VAX vaccine in 20 high-risk adults, finding 18 participants mounted significant immune responses with only mild adverse events and no cancer development at median 16.5 months.
- Lynch syndrome affects 1 in 279 people, increasing colorectal cancer risk up to 80 percent, prompting scientists to develop vaccines that train the immune system to intercept precancerous growths before they become tumors.
- In a separate study, Dr. Stacy Norton and 44 other Lynch carriers tested a vaccine designed to spot hundreds of mutations; Norton reported her colonoscopies were polyp-free for the first time since 2014.
- Researchers caution these trials measured safety and immune response rather than cancer prevention; the pancreatic study lacked a control group and enrolled a small, specific population.
- Larger clinical trials are expected to begin next year as scientists investigate whether vaccine-generated T cells reach precancerous tissue and potentially eliminate yearly surveillance colonoscopies for high-risk patients.
34 Articles
34 Articles
How Researchers Are Testing Vaccines To Stop Cancer Before It Starts
Researchers are testing an experimental vaccine designed to train the immune system to target precancerous cells before pancreatic cancer develops. According to the report, scientists at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins enrolled 20 people with an inherited risk of pancreatic cancer in an early-stage clinical trial focused on mutations in the KRAS gene.The report said KRAS mutations are responsible for more than 90 p…
Scientists redirect the defenses created by coronavirus vaccines to fight cancer
Associated Press News
Testing is underway on vaccines to intercept brewing colon cancer before it takes root
Scientists are creating a new kind of vaccine that teaches the immune system to intercept a type of brewing colon cancer before it turns into a full-fledged tumor.
Testing is underway in Houston on vaccines to intercept brewing colon cancer before it takes root
A Houston doctor who's helping to test a new vaccine is among an estimated 1 million Americans who have Lynch syndrome, a faulty gene passed from a parent that puts them at extremely high risk of colorectal cancer and more vulnerable to certain other cancers.
Coverage Details
Bias Distribution
- 53% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
